FR3122086B1 - Comprimé à sucer à base de PVPI dépourvu d’excipients cellulosiques. - Google Patents

Comprimé à sucer à base de PVPI dépourvu d’excipients cellulosiques. Download PDF

Info

Publication number
FR3122086B1
FR3122086B1 FR2104208A FR2104208A FR3122086B1 FR 3122086 B1 FR3122086 B1 FR 3122086B1 FR 2104208 A FR2104208 A FR 2104208A FR 2104208 A FR2104208 A FR 2104208A FR 3122086 B1 FR3122086 B1 FR 3122086B1
Authority
FR
France
Prior art keywords
pvpi
lozable
tablet based
cellulose excipients
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2104208A
Other languages
English (en)
Other versions
FR3122086A1 (fr
Inventor
Nadine Grislain
Luc Grislain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermowave Lda Pt
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR2104208A priority Critical patent/FR3122086B1/fr
Publication of FR3122086A1 publication Critical patent/FR3122086A1/fr
Application granted granted Critical
Publication of FR3122086B1 publication Critical patent/FR3122086B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L’invention concerne un comprimé à sucer de polyvinylpyrrolidone iodée (PVPI) dont la quantité en poids est inférieure ou égale à 100 mg et dépourvu d’excipient cellulosique. Ledit comprimé est destiné à être utilisé comme médicament dans le traitement de la sphère oropharyngée ou buccale, en particulier dans la prévention et/ou le traitement des maladies infectieuses.
FR2104208A 2021-04-22 2021-04-22 Comprimé à sucer à base de PVPI dépourvu d’excipients cellulosiques. Active FR3122086B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2104208A FR3122086B1 (fr) 2021-04-22 2021-04-22 Comprimé à sucer à base de PVPI dépourvu d’excipients cellulosiques.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2104208 2021-04-22
FR2104208A FR3122086B1 (fr) 2021-04-22 2021-04-22 Comprimé à sucer à base de PVPI dépourvu d’excipients cellulosiques.

Publications (2)

Publication Number Publication Date
FR3122086A1 FR3122086A1 (fr) 2022-10-28
FR3122086B1 true FR3122086B1 (fr) 2024-05-03

Family

ID=76034859

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2104208A Active FR3122086B1 (fr) 2021-04-22 2021-04-22 Comprimé à sucer à base de PVPI dépourvu d’excipients cellulosiques.

Country Status (1)

Country Link
FR (1) FR3122086B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1203792A (zh) * 1997-06-02 1999-01-06 张志宏 复方聚维酮碘口含片
TW200637564A (en) 2004-12-27 2006-11-01 Kowa Co Orally disintegrable solid preparation comprising povidone-iodine
EP2042160A1 (fr) * 2007-09-14 2009-04-01 Basf Se Comprimes orals pour le traitement de la cavite orale et le pharynx

Also Published As

Publication number Publication date
FR3122086A1 (fr) 2022-10-28

Similar Documents

Publication Publication Date Title
Wilkinson et al. Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease
Erdes et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults
MA30252B1 (fr) Vaccin therapeutique
Oo et al. AstraZeneca COVID-19 vaccine and Guillain-Barré Syndrome in Tasmania: A causal link?
JP2009526021A5 (fr)
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
JPH0818977B2 (ja) 精神分裂病治療用組成物
NO317855B1 (no) Anvendelse av selegilin eller et farmasoytisk akseptabelt salt derav.
JP2013531041A5 (fr)
Storms et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis
Khan et al. Design and evaluation of sustained release matrix tablet of flurbiprofen by using hydrophilic polymer and natural gum
Doody et al. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study
JP2009539821A (ja) ワクチンの舌下投与用医薬組成物、その調製方法およびその使用
FR3122086B1 (fr) Comprimé à sucer à base de PVPI dépourvu d’excipients cellulosiques.
RU2464023C2 (ru) Лекарственное средство для лечения фибромиалгии
EP1909767A2 (fr) Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees
MA45202B1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
US20120122993A1 (en) Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-(1r)-, methanesulfonate
ES2198948T3 (es) Usos de antagonistas de la substancia p para el tratamiento del sindrome de la fatiga cronica y/o de la fibromialgia.
WO2010026469A1 (fr) Composition pharmaceutique destinée à être utilisée dans le traitement des infections sexuellement transmissibles
US20200297732A1 (en) Pharmaceutical formulation
ES2314440T3 (es) Composicion farmaceutica bucodispersable de un compuesto antitrombotico.
CA2840521C (fr) Composition pharmaceutique pour traiter l'ejaculation prematuree et procede pour traiter l'ejaculation prematuree
JP2011006377A (ja) 沈降炭酸カルシウムを有効成分とする口腔内崩壊錠
US20070104782A1 (en) Modified release tablet formulations with enhanced mechanical properties

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20221028

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: DERMOWAVE LDA, PT

Effective date: 20230405

PLFP Fee payment

Year of fee payment: 4